The PML patients demonstrated lower overall CD8+ cytotoxic capacity and CD4+ T-cell activation capacity, suggesting that decreased immune function is a major risk factor for PML. The gene discussed is CD8A; the disease is progressive multifocal leukoencephalopathy.